Melanoma CT: Difference between revisions
Jump to navigation
Jump to search
Varun Kumar (talk | contribs) (Created page with "{{Melanoma}} {{CMG}} ==Overview== ==References== {{reflist|2}} Category:Disease Category:Types of cancer Category:Oncology Category:Dermatology {{WikiDoc...") |
No edit summary |
||
(9 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Melanoma}} | {{Melanoma}} | ||
{{CMG}} | {{CMG}} {{AE}} {{YD}}; {{SSK}} | ||
==Overview== | |||
Melanoma can appear as a [[soft tissue]] [[mass]] on [[Computed tomography|CT scan]]. [[Chest]] [[Computed tomography|CT scan]] is recommended for the [[diagnosis]] of [[Metastasis|metastatic]] [[Lesion|lesions]] in [[Patient|patients]] who have been [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IA-IV melanoma and for [[Prevention (medical)|secondary prevention]] of melanoma in [[Patient|patients]] who were previously [[Diagnosis|diagnosed]] with [[Cancer staging|Stage]] IIB-IV melanoma (annually for 5 years). | |||
== | ==CT Scan== | ||
*Melanoma can appear as a [[soft tissue]] [[mass]] on [[Computed tomography|CT scan]].<ref name="pmid25032021">{{cite journal |vauthors=Brant JM |title=Breathlessness with pulmonary metastases: a multimodal approach |journal=J Adv Pract Oncol |volume=4 |issue=6 |pages=415–22 |date=November 2013 |pmid=25032021 |doi= |url=}}</ref> | |||
*[[Chest]] [[Computed tomography|CT scan]] of [[Patient|patients]] with [[Lung|pulmonary]] [[Metastasis|metastatic]] [[Lesion|lesions]] can demonstrate enlarged [[Mediastinum|mediastinal]] [[Lymphadenopathy|adenopathy]].<ref name="pmid28029320">{{cite journal |vauthors=Powell CA |title=Pulmonary Infiltrates in a Patient With Advanced Melanoma |journal=J. Clin. Oncol. |volume=35 |issue=7 |pages=705–708 |date=March 2017 |pmid=28029320 |doi=10.1200/JCO.2016.69.9793 |url=}}</ref> | |||
*[[Computed tomography|CT scan]] along with other modalities can also be useful for the [[Cancer staging|staging]] of the [[disease]], therapy assessment, and [[prognosis]] determination.<ref name="pmid26204273">{{cite journal |vauthors=Perng P, Marcus C, Subramaniam RM |title=(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis |journal=AJR Am J Roentgenol |volume=205 |issue=2 |pages=259–70 |date=August 2015 |pmid=26204273 |doi=10.2214/AJR.14.13575 |url=}}</ref> | |||
*[[Chest]] [[Computed tomography|CT scan]] is the preferred choice of [[chest]] [[imaging]] modality and is recommended for the [[diagnosis]] of [[Metastasis|metastatic]] [[Lesion|lesions]] in the following conditions:<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | |||
:*In [[Patient|patients]] with [[Cancer staging|stage]] IA-IV melanoma<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | |||
:*For [[Prevention (medical)|secondary prevention]] of melanoma in [[Patient|patients]] who were previously [[Diagnosis|diagnosed]] with [[Cancer staging|stage]] IIB-IV melanoma (annually for 5 years)<ref name="pmid23584343">{{cite journal| author=Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A et al.| title=Melanoma, version 2.2013: featured updates to the NCCN guidelines. | journal=J Natl Compr Canc Netw | year= 2013 | volume= 11 | issue= 4 | pages= 395-407 | pmid=23584343 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23584343 }} </ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
[[Category: | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Medicine]] | |||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Surgery]] | |||
Latest revision as of 18:08, 4 January 2019
Melanoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Melanoma CT On the Web |
American Roentgen Ray Society Images of Melanoma CT |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.
Overview
Melanoma can appear as a soft tissue mass on CT scan. Chest CT scan is recommended for the diagnosis of metastatic lesions in patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma in patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years).
CT Scan
- Melanoma can appear as a soft tissue mass on CT scan.[1]
- Chest CT scan of patients with pulmonary metastatic lesions can demonstrate enlarged mediastinal adenopathy.[2]
- CT scan along with other modalities can also be useful for the staging of the disease, therapy assessment, and prognosis determination.[3]
- Chest CT scan is the preferred choice of chest imaging modality and is recommended for the diagnosis of metastatic lesions in the following conditions:[4]
References
- ↑ Brant JM (November 2013). "Breathlessness with pulmonary metastases: a multimodal approach". J Adv Pract Oncol. 4 (6): 415–22. PMID 25032021.
- ↑ Powell CA (March 2017). "Pulmonary Infiltrates in a Patient With Advanced Melanoma". J. Clin. Oncol. 35 (7): 705–708. doi:10.1200/JCO.2016.69.9793. PMID 28029320.
- ↑ Perng P, Marcus C, Subramaniam RM (August 2015). "(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". AJR Am J Roentgenol. 205 (2): 259–70. doi:10.2214/AJR.14.13575. PMID 26204273.
- ↑ 4.0 4.1 4.2 Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.